Match Document Document Title
US20150099695 C1q/TNF-RELATED PROTEIN-9 (CTRP9) AND USE IN PREVENTION AND TREATMENT OF METABOLIC DISORDERS  
Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an...
US20140378376 Dosage Regime for Apolipoprotein Formulations  
An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to...
US20120129766 METHODS OF TREATING FGF21-ASSOCIATED DISORDERS  
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods...
US20110301085 PROTEIN HYDROLYSATE AND PLANT STEROL CONTAINING COMPOSITION FOR IMPROVING SERUM LIPID PROFILE AND PREVENTING ATHEROSCLEROSIS  
The invention relates to a terapeutical composition comprising a protein hydrolysate and a plant sterol, wherein the weight ratio of the plant sterol to the protein hydrolysate is from 1:0.02 to...
US20140336113 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERLIPIDEMIA, FATTY LIVER, ATHEROSCLEROSIS AND OTHER DISORDERS ASSOCIATED WITH METABOLIC SYNDROME  
The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis,...
US20140155316 FIBROBLAST GROWTH FACTOR 1 PROTEIN FRAGMENTS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20110223156 REVERSIBLE GEL PROTEIN FORMULATION  
Reversible gel protein formulations, including pharmaceutical formulations, that inhibit protein aggregate formation are described, along with containers, e.g., a vial, ampoule or bottle; or an...
US20150065419 METHODS FOR TREATING METABOLIC DISORDERS USING FGF  
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
US20140147414 COMPOSITIONS AND METHODS FOR TREATMENT OF INTRACELLULAR DAMAGE  
Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a...
US20110002994 METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT  
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to...
US20130190226 RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF  
A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about...
US20140057832 USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE  
The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present...
US20130261054 METHODS FOR TREATMENT OF NEPHROTIC SYNDROME AND RELATED CONDITIONS  
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to MCD and MN, and conditions related to nephrotic syndrome, such as but not...
US20140194354 Methods for Treatment of Nephrotic Syndrome and Related Conditions  
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to...
US20140011737 COMPOSITIONS AND METHODS FOR REGULATING METABOLISM  
The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.
US20110030077 METHODS OF MODULATING THE ORGANIC SOLUTE AND STEROID TRANSPORTER (OSTalpha-OSTbeta) ACTIVITY AND TREATING ASSOCIATED CONDITIONS  
The present invention is directed to methods of modulating bile acid and lipid transport via the organic solute and steroid transporter Ostα-Ostβ. The present invention is further directed to...
US20140107029 Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content  
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles...
US20130052167 Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content  
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles...
US20110318423 Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content  
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles...
US20150165026 SINGLET OXYGEN-LABILE LINKERS AND METHODS OF PRODUCTION AND USE THEREOF  
Activatable compositions that include at least one functional moiety and at least one cleavable linker directly or indirectly linked to the at least one functional moiety are disclosed. The at...
US20150202259 TARGETED OESOPHAGEAL ADMINISTRATION OF ZN-ALPHA2-GLYCOPROTEINS (ZAG), METHODS AND FORMULATIONS THEREOF  
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to...
US20130065821 COMPOSITION FOR PREVENTING AND IMPROVING METABOLIC SYNDROME  
A method for improving blood HDL/LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, and/or reducing body weight, that includes ingesting a composition containing...
US20150226749 METHOD FOR ASSESSING A SUBJECT'S RISK OF HAVING A CARDIOVASCULAR DISEASE  
The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from...
US20130310315 METHOD FOR ASSESSING A SUBJECT'S RISK OF HAVING A CARDIOVASCULAR DISEASE  
The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from...
US20110177097 METHODS FOR MODULATING EXPRESSION OF CREB  
Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or...
US20110123521 METHODS FOR MODULATING EXPRESSION OF RBP4  
Methods are provided for modulating RBP4 by administering a RBP4-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or...
US20100329982 PARTICLES WITH INDUCIBLE CHANGE OF SHAPE  
The invention relates to particles which exhibit a stimulable shape change and allow control of their uptake in active cells. The particles can be used as carrier systems for bioactive molecules...
US20140371142 MYONECTIN (CTRP15), COMPOSITIONS COMPRISING SAME, AND METHODS OF USE  
Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein....
US20120028893 Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses  
Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis....
US20140228282 FIBROBLAST GROWTH FACTOR 21 PROTEINS  
This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for...
US20130210703 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9  
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat...
US20140105896 FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN  
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat...
US20140045747 METHODS FOR INCREASING AND MOBILIZING HEMATOPOIETIC STEM CELLS  
A method is provided for increasing the number of hematopoietic stem cells in the bone marrow, increasing the mobilization of these cells to migrate from the bone marrow to the bloodstream and...
US20110118173 METHOD OF DELIPIDATION OF HDL USING SERUM OPACITY FACTOR TO PREVENT, INHIBIT, AND/OR REVERSE ATHEROSCLEROSIS  
This invention relates to delivering a therapeutically active serum opacity factor or an anti-atherosclerotic therapeutic lipoprotein generated from interaction with serum opacity factor to an...
US20150238568 EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES  
Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained...
US20130172250 Exendins To Lower Cholesterol And Triglycerides  
Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained...
US20110263496 EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES  
Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained...
US20120214734 TREATMENT OF METABOLIC DISORDERS  
The present invention provides methods for treating, preventing, and/or delaying the onset of metabolic disorders including multi-factorial syndromes such as insulin-insensitivity and metabolic...
US20150064255 NANOSTRUCTURES FOR TREATING CANCERS AND OTHER CONDITIONS  
Nanostructures, compositions and methods for treating cancers and other conditions are provided. In some cases, the nanostructures and/or compositions may be used to treat cancers or other...
US20140018293 MINIMIZING INTESTINAL DYSFUNCTION  
Techniques are discloded for treating or reducing sumptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of...
US20150250725 METHOD FOR PRODUCING A LIPID PARTICLE, THE LIPID PARTICLE ITSELF AND ITS USE  
A method for producing a lipid particle comprising the following: i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising...
US20140073563 FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME  
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to...
US20120142582 Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders  
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central...
US20080020972 Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependent diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy  
Human Chorionic Gonadotropin administered by intramuscular route is traditionally used for the treatment of sterility and cryptorchidism. After numerous tests performed, a compound to be...
US20120289460 Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases  
This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at...
US20140057838 OSTEOBLAST-EXPRESSED LIPOCALIN 2 REGULATES GLUCOSE METABOLISM  
Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and...
US20140235535 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY  
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are...
US20060205643 Treatment of inflammatory conditions of the intestine  
A method for the treatment and/or prophylaxis of an inflammatory condition of the intestine of a patient, comprises parenteral administration to the patient of an effective amount of high density...
US20070141136 Method of treating insulin resistance, adult onset diabetes and metabolic syndrome X  
A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in a mammalian subject is accomplished by intravenously administering to a...
US20140256621 ENGINEERED POYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY  
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides...